Leqembi® Pen subcutaneous formulation approved in Japan

BioArctic partner Eisai announced approval of a subcutaneous autoinjector formulation of Leqembi, marketed as Leqembi Pen in Japan, as a new administration route for early-stage disease treatment. The approval could improve treatment convenience and expand access versus infusion-based administration, providing a positive commercial catalyst for Eisai and BioArctic.